Oct 08th 2013 - Edison Investment Research today published a report on Prima Biomed entitled "A Blessing In Disguise?". In summary, the report says:
The lack of a clear PFS signal in the CAN-003 Phase II trial of CVac in ovarian cancer is undoubtedly a setback, but does at least provide an opportunity for Prima to amend its CANVAS Phase II/III study to make overall survival its primary endpoint. This would clearly be more appropriate given the growing evidence of the late-onset efficacy phenomenon with cancer immunotherapy. However, enrolment into CANVAS has been temporarily suspended, pending evaluation of as yet immature OS data from CAN-003, and its resumption will now require some efficacy signal to be present. Even under this best case scenario, the CANVAS study read-out would be later than before.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »